skip to main content

Dual antiplatelet bleeding risk — GPhC CRA MCQ

Instant feedback + full explanation. One question, done properly.

HardCardiovascular TherapeuticsDual antiplatelet bleeding riskGPhC CRA

A patient completed 12 months of ticagrelor 90 mg twice daily after MI and remains at high ischaemic risk without major bleeding. Which extended regimen may a specialist select?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: D — Ticagrelor 60 mg twice daily with low-dose aspirin

For selected adults at high atherothrombotic risk who tolerated the first year after MI, extended ticagrelor uses 60 mg twice daily with aspirin. The decision is specialist-led and balances recurrent ischaemia against bleeding; 90 mg twice daily is the usual first-year dose.

Reference: BNF: ticagrelor: https://bnf.nice.org.uk/drugs/ticagrelor/